Arcutis Biotherapeutics, Inc. (ARQT) company profile
Close on Nov 17, 2026Market cap $3.44BP/E 124.2Yield –
About Arcutis Biotherapeutics
Pharmaceutical Preparations, SIC 2834
This commercial-stage biopharmaceutical enterprise develops and markets treatments for immune-mediated skin disorders. The business concentrates on dermatological therapies, offering topical roflumilast formulations under the ZORYVE brand in cream and foam formats. These commercialized products are prescribed for conditions including plaque psoriasis, atopic dermatitis, and seborrheic dermatitis across various adult and pediatric age groups. In addition to commercial assets, development efforts encompass an experimental biologic fusion protein, ARQ-234, aimed at inflammatory conditions. Target prescribers and healthcare customers primarily include dermatologists, pediatricians, and primary care physicians caring for patients with chronic inflammatory skin diseases.
Operations and commercial distribution are established in the United States and Canada, supplemented by international licensing and collaboration partnerships covering Japan, Greater China, and Southeast Asia. The provided filing text does not disclose the enterprise's corporate headquarters location or physical facility metrics.
Summary of the business section of Arcutis Biotherapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Arcutis Biotherapeutics, Inc.
- Headquarters
- Westlake Village, CA
- Address
- 3027 Townsgate Road, Suite 300 91361
- Phone
- (805) 418-5006
- Website
- arcutis.com
- Employees
- 354, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Los Angeles, California
Stock & identifiers
- Ticker
- ARQT
- Exchange
- Nasdaq
- IPO date
- Jan 31, 2020
- Shares outstanding
- 126M, Jul 31, 2026
- Public float
- $1.53B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1787306
- CUSIP
- 03969K108
- ISIN
- US03969K1088
- FIGI
- BBG00QN8K4M4
- Share class FIGI
- BBG00QN8K4P1
- EIN
- 81-2974255
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Todd Watanabe | See Remarks, Director | 895,140 |
| Patrick Burnett | EVP, Chief Medical Officer | 116,649 |
| Robert Lisicki | EVP, Chief Commercial Officer | 55,000 |
| Masaru Matsuda | EVP, Chief Legal Officer | 111,289 |
| Latha Vairavan | SVP Chief Financial Officer | 85,978 |
| Larry Todd Edwards | See Remarks | 175,178 |
| David Joseph Topper | Chief Financial Officer | 182,774 |
| Robert A. Scott | Director | 20,342 |
| Howard G. Welgus | Director | 60,198 |
| Terrie Curran | Director | 23,526 |
| Christopher Peetz | Director | 191,815 |
| Sue-Jean Lin | Director | 27,567 |
| Patrick J. Heron | Director | 59,661 |
| Keith R. Leonard | Director | 29,651 |
| Halley E. Gilbert | Director | 27,901 |
| Neha Krishnamohan | Director | 27,901 |
| Amit Munshi | Director | 9,799 |
| Bhaskar Chaudhuri | Director | 917,807 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $7.22M | $20.35M | $2.41M | $103 | $120 |
| FY2024 | $3.69M | $11.21M | $2.73M | $50 | $91 |
| FY2023 | $4.94M | -$1.16M | $1.62M | $11 | $92 |
| FY2022 | $4.58M | $2.42M | $2.31M | $53 | $89 |
| FY2021 | $4.82M | $441.90K | $3.07M | $74 | $99 |
| FY2020 | $2.75M | $16.77M | $4.06M | $129 | $133 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Todd Franklin Watanabe President and Chief Executive Officer | $713.33K | $2.07M | $3.85M | $579.58K | $14.00K | $7.22M | +96% |
| Latha Vairavan Chief Financial Officer | $419.49K | $440.41K | $839.46K | $213.40K | $12.02K | $1.92M | – |
| Patrick E. Burnett, M.D., Ph.D. Chief Medical Officer | $535.00K | $752.95K | $1.38M | $334.38K | $14.00K | $3.02M | +20% |
| L. Todd Edwards Chief Commercial Officer | $535.00K | $752.95K | $1.38M | $334.38K | $27.83K | $3.03M | +54% |
| Masaru Matsuda, J.D. Chief Legal Officer | $495.17K | $465.46K | $865.04K | $278.53K | $14.00K | $2.12M | +22% |
| David Topper Former Chief Financial Officer | $196.46K | $465.46K | $865.04K | – | $419.77K | $1.95M | -63% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jan 31, 2020
- Offer price
- $17.00
- Securities offered
- 9,375,000
- Gross proceeds
- $159.38M
- Exchange
- Nasdaq
- First trading day
- Jan 31, 2020
- First-day close
- $21.80+28.2%
- Lock-up ends (est.)
- Jul 29, 2020
“The initial public offering price is $17.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 354 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jan 31, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Jan 21, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |
| Sep 9, 2019 | Name change | Name changed from Arcutis, Inc. to Arcutis Biotherapeutics, Inc. |
See a number that looks wrong?